Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 studyMLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with
03:15 EST 11 Dec 2012 | Takeda
More From BioPortfolio on "Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 studyMLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
